Median Technologies reports its financial results for H1 2019
Press release – For immediate release – 5:45 pm CEST
Median Technologies reports its financial results for H1 2019
- H1 revenue up 19.5% to € 4 million, driven by iCRO business
- Order backlog up 30% to € 30.7 million
- Significant decrease of operating expenses
- Cash and cash equivalents of € 7.9 million
Median Technologies (ALMDT), The Imaging Phenomics Company®, today announced its results for the first half of 2019.
The company’s Board of Directors met on October 1st and approved the consolidated financial statements for the first half of 2019.
With € 4 million in revenue, Median Technologies’ sales increased 19.5% compared to the first half of 2018. The company’s H1 revenue came solely from its iCRO business .
During the first six months of 2019, Median Technologies continued to invest in the development of its imaging phenomics platform, iBiopsy® and strengthened its AI and data science teams in order to cement its position as a leader in the field.
As Median started managing operations locally in China, the company’s iCRO Business Unit continued to expand, which resulted in a significant increase of Chinese orders throughout the half of the year. In Europe and the United States, new orders in the first half of 2019 exceeded the company’s expectations for the entire year. As of June 30, Median’s iCRO business unit was operationally at its break-even point.
Simplified financial statements (IFRS consolidated)
|In thousands of euros (audited figures)||H1 2019||H1 2018|
|Revenue from ordinary activities||4,041||3,358|
|Net financial result||-12||127|
The company’s operating expenses dropped sharply compared to last year due to a 36% decrease in staff costs (€ -4.1 million as of June 30, 2019 vs. € -6.5 million as of June 30, 2018) and a 37% decrease in external costs (€ -3.5 million as of June 30, 2019 vs. € -5.6 million as of June 30, 2018).
As a result, the operating loss was cut by more than 50% to € -4.19 million. The company’s net result at the half-year mark went from € -9.0 million in 2018 to € -4.2 million in 2019.
As of June 30, 2019, Median had € 7.9 million in cash and cash equivalents, not including the Research Tax Credit payment (€1.6 million) which was received in July, and € 4.9 million in net equity. Net new orders reached € 11 million in the first half of the year bringing the company’s order backlog to € 30.7 million, up € 7 million compared to December 31, 2018. The extent of the order backlog makes Median confident about the company’s revenues for the second half of 2019 and 2020.
Latest developments and perspectives
During the third quarter of 2019, Median Technologies has continued negotiations for a € 35 million loan with the European Investment Bank (EIB), however the process was slowed down due to EIB logistical internal constrains. EIB and Median expect to finalize the agreement in Q4. Median expects the lending of the first tranche of € 15 million in the first half of 2020. Structured in three tranches, the loan will enable Median Technologies to boost investments in its imaging phenomics platform, iBiopsy®, over the next few years. The ongoing negotiations for this loan were announced on May 15th.
Current trends point to the company’s positive results in the third quarter of 2019. Q3 results will be published shortly. Median’s iCRO business is expected to keep growing steadily worldwide. In the United States, two phase III contracts (totaling € 2 million) were signed in Q2, with one of the world’s top 3 pharmaceutical companies, a new customer for Median. These contracts have opened promising opportunities for Median in the US. The development of iBiopsy® is progressing as planned, including an upcoming technology demonstrator at the annual convention of the RSNA (Radiological Society of North America) in early December.
“Our results for H1 have exceeded all expectations. We anticipate keeping up the momentum in the second half of the year,” said Fredrik Brag, CEO and co-founder of Median.
Median informs its shareholders and the financial community at large that its financial statements for the first half of 2019 have been filed with the French market regulator and are now available on the company’s website.
Forward-Looking Statements: This press release contains forward-looking statements. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions and expectations with respect to future financial results, events, operations, services, product development and potential, and statements regarding future performance. Forward-looking statements are generally identified by the words “expects”, “anticipates”, “believes”, “intends”, “estimates”, “plans” and similar expressions. Although Median’s management believes that the expectations reflected in such forward looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Median, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, the uncertainties inherent in research and development, future clinical data and analysis, including post marketing, decisions by regulatory authorities such as the absence of guarantee that the service if approved will be commercially successful, the future approval, Median’s ability to benefit from external growth opportunities, to complete related transactions and/or obtain regulatory clearances, risks associated with intellectual property, trends in exchange rates and prevailing interest rates, volatile economic conditions, the impact of cost containment initiatives and subsequent changes thereto, the average number of shares outstanding as well as those discussed or identified in the public filings with the AMF made by Median, other than as required by applicable law, Median does not undertake any obligation to update or revise any forward-looking information or statements.
 imaging Contract Research Organization
About Median Technologies
Median Technologies provides innovative imaging solutions and services to advance healthcare for everyone. We leverage the power of Imaging Phenomics to provide insights into novel therapies and treatment strategies. Our unique solutions for medical image analysis and management in oncology trials and iBiopsy® for imaging phenotyping, together with our global team of experts, are advancing the development of new drugs and diagnostic tools to monitor disease and assess response to therapy. Median Technologies supports biopharmaceutical sponsors and healthcare professionals around the world to quickly and precisely bring new treatments to patients in need. This is how we are helping to create a healthier world.
Founded in 2002, based in Sophia-Antipolis, France, with a subsidiary in the US and another one in Shanghai, Median is listed on Euronext Growth market (ISIN: FR0011049824, ticker: ALMDT). Median has received the “Innovative Company” label from BPI France, is eligible for the French SME equity savings plan scheme (PEA-PME), is listed on the Enternext® PEA-PME 150 index and has been awarded the Euronext European Rising Tech label.
Head of Corporate and Marketing Communications
+33 6 10 93 58 88
+33 1 56 88 11 11
Alizé RP (Press)
+33 6 64 18 99 59